Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Down 29.3% in June

Vincerx Pharma, Inc. (NASDAQ:VINC) was the target of a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 433,200 shares, a decline of 29.3% from the May 31st total of 612,500 shares. Based on an average daily trading volume, of 717,900 shares, the short-interest ratio is currently 0.6 days.

Vincerx Pharma Stock Up 9.5 %

Vincerx Pharma stock opened at $0.81 on Monday. The company has a market capitalization of $23.92 million, a PE ratio of -0.45 and a beta of 1.41. Vincerx Pharma has a 12-month low of $0.57 and a 12-month high of $9.37. The firm’s fifty day moving average is $0.73 and its 200 day moving average is $2.06.

Vincerx Pharma (NASDAQ:VINC) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). Sell-side analysts expect that Vincerx Pharma will post -0.62 EPS for the current fiscal year.

Hedge Funds Weigh In On Vincerx Pharma

A hedge fund recently raised its stake in Vincerx Pharma stock. Vanguard Group Inc. increased its stake in shares of Vincerx Pharma, Inc. (NASDAQ:VINC) by 29.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 666,995 shares of the company’s stock after buying an additional 153,575 shares during the quarter. Vanguard Group Inc. owned 3.12% of Vincerx Pharma worth $3,375,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 44.02% of the company’s stock.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Vincerx Pharma in a report on Tuesday, April 9th.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.